Regeneron’s Arcalyst Fails to Win U.S. Backing for Gout

Regeneron Pharmaceuticals Inc., the maker of the autoinflammatory drug Arcalyst, failed to win U.S. approval to expand the use of the medicine for patients undergoing gout treatments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.